3 results
Approved WMORecruiting
The objective is to determine whether etidronate can halt or attenuate disease progression in patients with Fahr*s disease or syndrome.
Approved WMORecruiting
Primary Objective To determine if 24 months of treatment with etidronate halts the progression of arterial calcification in the legs and carotid siphons. Secondary Objectives 1. To determine the effect of 24 months of treatment with etidronate on…
Approved WMORecruiting
The primary objective is to compare the pharmacological profile of the magistral form of dexamphetamine sulphate to the pharmacological profile of the brand-name form of dexamphetamine (Tentin©) in adult patients diagnosed with attention deficit…